AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-67. (Cancelled)

68. (Currently amended) An isolated proteinaceous molecule having serine proteinase activity, ~~or a fragment thereof,~~ comprising an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 5, or by a nucleotide sequence capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO: 5 or its ~~complimentary~~complementary form under high stringency conditions, wherein the high stringency conditions comprise hybridization conditions of ~~about~~ 31% v/v to ~~about~~ 50% v/v formamide and ~~about~~ 0.01M to ~~about~~ 0.15M salt at 42°C and washing conditions of ~~about 0.01M to about 0.15M salt at 42°C~~0.1xSCC, 0.5% w/v SDS at 60°C.

69-70. (Cancelled)

71. (Currently amended) An isolated proteinaceous molecule having serine proteinase activity, ~~or a fragment thereof,~~ comprising an amino acid sequence as set forth in SEQ ID NO: 6.

72-73. (Cancelled)

74. (Currently amended) An isolated glycosylation variant of a proteinaceous molecule having serine proteinase activity, ~~or a fragment thereof,~~ wherein said glycosylation variant is encoded by a nucleotide sequence capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO: 5 or its ~~complimentary~~complementary form under high stringency conditions, wherein the high stringency conditions comprise hybridization conditions of ~~about~~ 31% v/v to ~~about~~ 50% v/v formamide and ~~about~~ 0.01M to ~~about~~ 0.15M salt at 42°C and washing conditions of ~~about 0.01M to about 0.15M salt at 42°C~~0.1xSCC, 0.5% w/v SDS at 60°C.

75. (Currently amended) A composition comprising a proteinaceous molecule~~, or a fragment thereof,~~ according to any one of Claims 68, 71 and 78 and one or more pharmaceutically acceptable carriers or diluents.

76. (Currently amended) A composition comprising a glycosylation variant~~, or fragment thereof,~~ according to ~~any one of Claims~~Claim ~~74, 81 and 82~~ and one or more pharmaceutically acceptable carriers or diluents.

77. (Cancelled)

78. (Currently amended) An isolated proteinaceous molecule~~, or a fragment thereof~~, wherein said proteinaceous molecule is encoded by a nucleic acid comprising the nucleotide sequence as set forth in SEQ ID NO: 5.

79-83. (Cancelled)

84. (New) An isolated proteinaceous molecule having serine proteinase activity, comprising an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 5, or by a nucleotide sequence capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO: 5 or its complementary form under high stringency conditions, wherein the high stringency conditions comprise hybridization conditions of 31% v/v to 50% v/v formamide and 0.01M to 0.15M salt at 65°C and washing conditions of 0.1xSCC, 0.5% w/v SDS at 60°C.

85. (New) An isolated glycosylation variant of a proteinaceous molecule having serine proteinase activity, wherein said glycosylation variant is encoded by a nucleotide sequence capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO: 5 or its complementary form under high stringency conditions, wherein the high stringency conditions comprise hybridization conditions of 31% v/v to 50% v/v formamide and 0.01M to 0.15M salt at 65°C and washing conditions of 0.1xSCC, 0.5% w/v SDS at 60°C.